Compliance with treatment · children with SCD who have been receiving prophylactic penicillin for at least two years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deaths · children with SCD
Summary of findings ‐ initiation of penicillin prophylaxis showed no clear difference in deaths compared with placebo (low certainty).
1 finding from 1 review
Adverse effects · children with SCD
1 finding from 1 review
Antibiotic‐resistant organisms isolated · children with SCD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Requirement of other courses of antibiotics · children with SCD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Compliance with treatment · children with SCD
1 finding from 1 review
Incidence of S pneumoniae Confirmed bacterial infection · children with SCD who have been receiving prophylactic penicillin for at least two years
Summary of findings ‐ withdrawal of penicillin prophylaxis showed no clear difference in incidence of S pneumoniae Confirmed bacterial infection compared with continuation (low certainty).
1 finding from 1 review
Deaths · children with SCD who have been receiving prophylactic penicillin for at least two years
1 finding from 1 review
Nausea and vomiting · children with SCD who have been receiving prophylactic penicillin for at least two years
Summary of findings ‐ withdrawal of penicillin prophylaxis showed no clear difference in adverse effects: incidences of nausea and vomiting compared with continuation (low certainty).
1 finding from 1 review
Annual rate of change in % predicted FEV1 All participants · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FEV1 Subgroup: under 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FEV1 Subgroup: over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC All participants · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Under 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Transmission‐related outcomes: hospitalization ‐ Number or proportion of hospital admissions · adults and children with cystic fibrosis
Summary of findings: non‐steroidal anti‐inflammatory drugs showed no clear difference in proportion with at least 1 hospital admission compared with placebo (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people without inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors
1 finding from 1 review
Proportion with zero bleeds · people without inhibitors
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in proportion of participants with zero bleeds compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
1 finding from 1 review